Integra LifeSciences Holdings Corporation (IART) — Fair Value Analysis

Base-case fair value (P50): $12.99 · Current price: $18.34 · Verdict: Overvalued

The Verdict on IART

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is currently considered Fairly Valued according to our Monte Carlo simulations, despite its current trading price of $18.34. Our median fair value (P50) assessment for IART stands at $12.99, indicating a -29.2% divergence from its present market price. This suggests that while there isn't significant implied upside from current levels, the stock's valuation is largely aligned with its intrinsic potential based on our probabilistic models.

How IART stacks up against peers

IART's quality tier is rated as average, reflecting its operational and financial health relative to its sector peers. This average quality assessment is integrated into our Monte Carlo simulations, influencing the range and probability of future cash flows used to determine its $12.99 fair value. The fact that the stock trades at $18.34 with a median fair value of $12.99 suggests the market is largely factoring in this average performance profile. Investors should note this alignment when considering IART's near-term prospects.

What this means for investors

For investors tracking IART, the Fairly Valued verdict and the -29.2% gap between the $18.34 and our $12.99 median fair value implies that the stock may not offer a compelling entry point for significant immediate capital appreciation based purely on valuation discrepancies. While our simulations point to a $12.99 of $12.99, it's crucial to understand the full distribution of potential outcomes, including both downside and bull case scenarios. Sign up for FairCurve to see the full bear/bull distribution for IART and track its fair value as new fundamentals are released.